Dana Narvaez, Oncologist at Alexander Fleming Institute, Global Oncology Subcommittee (Community of Practice – Health Policy) at American Society of Clinical Oncology, shared a post on LinkedIn:
“Our new publication: “Physician treatment decisions for HR+/HER2– early breast cancer in young patients: a Latin American survey” is out now in Therapeutic Advances in Medical Oncology
How oncologists across 17 countries manage early HR+/HER2– breast cancer in young women.
The study reveals significant heterogeneity in treatment decisions for young women with early HR+/HER2– breast cancer across Latin America.
These decisions were influenced by:
- The physician’s focus of care (breast cancer specialist vs. general oncologist)
- Physician gender
- The availability of diagnostic and therapeutic resources
Deeply proud of this collaborative work from LATAM.”
Title: Physician treatment decisions for hormone receptor-positive, HER2-negative early breast cancer in young patients: a Latin American survey
Authors: Dana Narvaez, Federico Waisberg, Cynthia Villarreal-Garza, Sergio Rivero, Cristian Alexis Ostinelli, Matías Chacón, Fernando Namuche Ojeda, Alvaro Encinas Casanave, María Lucila González Donna, Cinthia Gauna, Juana Vazquez, María Paulina Molina Espinosa, Sara C. Altuna Mujica, Ronald Limón, Kayra Sanchez Muñoz, Claudia Martinez, Vanesa Lopez, Edgar Danilo Aguirre, Adrian Nervo, Gonzalo Gomez Abuin, Andrea Aguilar, Victoria Costanzo, Santiago R. Bella, Pablo Mandó, Valeria Caceres
Read the Full Article.
More posts featuring Dana Narvaez.